A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

The purpose of this study is to evaluate the safety of oral azacitidine (CC-486) when
combined with R-CHOP (the treatment regimen normally used in treating Diffuse large B-cell
lymphoma or Grade 3B follicular lymphoma). This study also proposes to explore the
pharmacokinetics of oral azacitidine when administered in combination with R-CHOP and to
assess the effects the drug can have on the human body, as well as the ability of CC 486 in
combination with R CHOP to further effect the response of tumors associated with Diffuse
large B-cell lymphoma or Grade 3B follicular lymphoma, .

Oral azacitidine in combination with R-CHOP has not been approved for the treatment of
Diffuse large B-cell lymphoma or Grade 3B follicular lymphoma and its use in this study is
investigational. Various dose levels of this investigation treatment will be administered to
subject enrolled into the study.

This study is separated into three periods: Screening and Registration, Treatment and
Follow-up periods. Before the patient can receive the study drug the doctor will perform
tests to find out whether he/she can participate in the study. This is done during the
Screening Period. If the patient and the treating physician determine that the patient is
eligible to participate in the study, the patient will be registered in the study and
assigned to receive one of the investigational dose levels of oral azacitidine.

The Treatment period starts when the patient receives their first dose of the study drug. The
maximum time the patient will receive study treatment is 5 months. The intent is for the
patient to complete 6 cycles of treatment. Each cycle will be 21 days. The Follow-up period
starts when the patient's treatment is completed or discontinued for any reason. The patient
will have fewer exams, tests and visits once entering the follow-up period. These visits will
be every 6 months for up to 2 years.

Inclusion Criteria:

1. Histologically confirmed previously untreated DLBCL or Grade 3B FL, [double-positive
for BCL2 and c-MYC] or transformed lymphoma. Transformed lymphoma from FL or marginal
zone lymphoma, but not chronic lymphocytic leukemia (CLL) [Richter Transformation] are
allowed as long as no prior anti-lymphoma therapy of any kind has been administered.

1. A formalin fixed paraffin embedded lymph node or tumor biopsy specimen must be
submitted during the Screening Period. The specimen must have been acquired by a
surgical or core needle biopsy (≥ 2 cores at baseline); material from a fine
needle aspiration is not acceptable.

2. Fresh core biopsy, frozen, must be performed before start of therapy and
submitted for storage. This is optional only for the subjects who have a
biopsy-accessible site and consent to the procedure. In case no prior fixed
formalin paraffin embedded (FFPE) biopsy is available, this specimen can also be
used for diagnostic confirmation.

3. No prior anti-lymphoma therapy. However, for subjects with bulky disease,systemic
symptoms, compressive disease, or rapidly progressing adenopathies, pre-phase
treatment with 1 mg/kg/day prednisone, or equivalent, for a maximum of 7 days is
permitted prior to Cycle 1 Day -6 at the discretion of the Investigator. In
exceptional cases, if clinically indicated, a higher dose of steroids and/or a
slightly longer duration is allowed for the purpose of urgent symptom management,
and the subjects is considered eligible. A washout period does not apply. However
the fresh core biopsy mentioned above should be performed before starting
prednisone.

2. International Prognostic Index score ≥ 2 or DLBCL with double-positive for BCL2 and
c-MYC by IHC (immunohistochemistry) or FISH (fluorescent in situ hybridization) based
on local pathology lab assessment.

3. Measurable disease on cross section imaging by CT (computed tomography) that is at
least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions as
defined by IWG (International Working Group) response criteria for NHL (non-Hodgkin
Lymphoma).

4. Ann Arbor stage II to IV.

5. Men and women 18 years of age to 80 years of age of any ethnic origin or race at the
time of signing the ICD.

6. Understand and voluntarily sign an ICD (Informed Consent Document) prior to any study
related assessments/procedures are conducted.

7. Able to adhere to the study visit schedule and other protocol requirements.

8. Performance status ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale.

9. Negative serum pregnancy test within 72 hours before starting study treatment on Cycle
1 Day -6 for females of childbearing potential (FCBP). A female of child-bearing
potential, defined as a sexually mature woman who: 1) has not undergone a hysterectomy
(the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal
of both ovaries) or, 2) has not been naturally postmenopausal for at least 24
consecutive months (i.e., has had menses at any time during the preceding 24
consecutive months), may participate providing they agree to the following conditions:

1. Either commit to true abstinence* from heterosexual contact (which must be
reviewed on a monthly basis) or agree to the use of a physician-approved
contraceptive method (oral, injectable, or implantable hormonal contraceptive;
tubal ligation; intrauterine device; barrier contraceptive with spermicide; or
vasectomized partner) without interruption, while on CC-486 (including dose
interruptions); and for 3 months following the last dose of IP; and

2. Agree to have a medically supervised serum pregnancy test with sensitivity of at
least 25 mIU/mL obtained at Screening. A serum pregnancy test is to be performed
within 72 hours prior to Day 1 of starting study therapy on Cycle 1 Day -6, and
within 72 hours prior to Day 1 of every subsequent cycle, and at the Treatment
Discontinuation Visit. The subject may not receive IP until the Investigator has
verified that the result of the pregnancy test is negative.

10. Male subjects with a female partner of childbearing potential must either commit to
true abstinence* or agree to the use of a physician-approved contraceptive method
throughout the course of the study and avoid fathering a child during the course of
the study and for 3 months following the last dose of the IP (Investigational
Product).

Exclusion Criteria:

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from participating in the study.

2. Any condition including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study.

3. Any condition that confounds the ability to interpret data from the study.

4. Any condition causing an inability to swallow tablets.

5. History of inflammatory bowel disease (e.g., Crohnis disease, ulcerative
colitis),celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or
any other gastrointestinal disorder or defect that would interfere with absorption,
distribution, metabolism, or excretion of the IP and/or predispose the subject to an
increased risk of gastrointestinal toxicity.

6. Hematologic and Non-hematologic exclusion criteria before start of therapy.

7. Seropositive for or active viral infection with hepatitis B virus (HBV):

1. Hepatitis B surface antigen (HBsAg) positive

2. HBsAg negative, anti-HBs positive and/or anti-HBc positive and detectable viral
DNA

3. Subjects who are HBsAg negative, anti-HBs positive, and/or anti-HBc positive, but
viral DNA negative are not eligible

4. Subjects who are seropositive because of HBV vaccination are eligible (HBV
surface antibody positive, HBV core antibody negative, and HBV surface antigen
negative)

8. Prior history of malignancies, other than diffuse large B-cell lymphoma, unless the
subject has been free of the disease for ≥ 5 years from the signing of the ICD.
Exceptions to the ≥ 5 year time limit include history of the following:

1. Basal cell carcinoma of the skin

2. Squamous cell carcinoma of the skin

3. Carcinoma in situ of the cervix

4. Carcinoma in situ of the breast

5. Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)

9. Known seropositive for or active infection with hepatitis C virus (HCV)

10. Known seropositive for or active viral infection with human immunodeficiency virus
(HIV).

11. Known or suspected hypersensitivity to azacitidine or mannitol or any other ingredient
used in the manufacture of oral azacitidine (see the current azacitidine IB).

12. Contraindication to any drug in the chemotherapy regimen, and specifically

1. LVEF < 50%

2. Corrected QT interval > 480 msec (using the Fridericia formula)

3. Neuropathy uropathy europathy Nemediastinal DLBCL.

13. Primary mediastinal DLBCL.

14. Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing
signs/symptoms related to the infection without improvement despite appropriate
antibiotics, antiviral therapy, and/or other treatment)

15. Significant active cardiac disease within the previous 6 months from the signing of
the ICD, including:

1. New York Heart Association (NYHA) class III or IV congestive heart failure

2. Unstable angina or angina requiring surgical or medical intervention; and/or

3. Myocardial infarction

16. Pregnant or lactating (breastfeeding) females.